SCHEMBL4834265

SCHEMBL4834265

CCOP(=O)(Cc1ccc(NC(=O)/C=C/c2snnc2-c2ccc(F)cc2)cc1)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 2/20 0.40
SNCA P37840 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HDAC1 Q13547 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MMP1 P03956 4/20 0.37
MMP2 P08253 4/20 0.37
MMP9 P14780 4/20 0.37
MAPT P10636 3/20 0.37
EGFR P00533 1/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
CDK19 Q9BWU1 1/20 0.37
HPSE Q9Y251 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831233 0.92 NPC1 (0.39) SNCAMEN1KMT2AHDAC1TDP1
SCHEMBL4834235 0.88 SNCA (0.41) SNCAMEN1KMT2ATDP1MMP1
SCHEMBL4834217 0.88 SNCA (0.41) SNCAMEN1KMT2ATDP1MMP1
SCHEMBL4827010 0.86 BTK (0.40) BTKSNCAMEN1KMT2AHDAC1
SCHEMBL4829181 0.80 HDAC1 (0.46) MEN1KMT2AHDAC1MAPTRAB9A
SCHEMBL4834255 0.80 MAOB (0.41) SNCAMEN1KMT2ATDP1MMP1
SCHEMBL4834273 0.80 MAOB (0.41) SNCAMEN1KMT2ATDP1MMP1
SCHEMBL27612956 0.79 MAOB (0.44) SNCAMEN1KMT2ATDP1MMP1
SCHEMBL4831239 0.79 MAOB (0.43) SNCAMEN1KMT2ATDP1MMP1
SCHEMBL4831227 0.79 MAOB (0.43) SNCAMEN1KMT2ATDP1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 BTK 3555/4885SNCA 1545/4885MEN1 3516/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 BTK 3555/4885SNCA 1545/4885MEN1 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.